Intra-Cellular Therapies has received positive analyst ratings in the last quarter, with no bearish or indifferent ratings. The average 12-month price target has increased by 4.17% from the previous target, indicating a positive outlook for the stock. This is likely to have a positive short-term impact on the stock price.